SLAMF7 and Miyoshi myopathy: Pazina et al. have recently reported that elotuzumab enhanced the SLAMF7–SLAMF7 interactions between NK cells and MM cells in a CD16-independent manner, which induced the cytotoxicity of the former toward the latter population (Figure 4D) [86].